Ecological effects of cefepime use during antibiotic cycling on the Gram-negative enteric flora of ICU patients

Abstract

This study examines the impact of cefepime and APP-β (antipseudomonal penicillin/ β-lactamase inhibitor combinations) on Gram-negative bacterial colonization and resistance in two Australian ICUs. While resistance did not cumulatively increase, cefepime (but not APP-β treatment) was associated with acquisition of antibiotic resistant Enterobacteriaceae, consistent with an ecological effect. Analysis of the resident gut E. coli population in a subset of patients showed an increase in markers of horizontal gene transfer after cefepime exposure that helps explain the increase in APP-β resistance and reminds us that unmeasured impacts on the microbiome are key outcome determinants that need to be fully explored.

Electronic supplementary material

The online version of this article (10.1186/s40635-018-0185-2) contains supplementary material, which is available to authorized users.

To the Editor,

Effects of late-generation cephalosporins such as cefepime (FEP) on resistance acquisition and the gut microflora are uncertain [1–4]. In a previous study in two Australian ICUs, nearly 70% of all prescriptions were allocated in respective cycles to either cefepime or an antipseudomonal penicillin/β-lactamase inhibitor (APP-β) like piperacillin/tazobactam [5]. Under this strong sustained selection, cefepime exposure resulted in more methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa colonization and infection than APP-β despite equivalent in vitro susceptibility [5]. In order to determine whether clinically important Enterobacteriaceae were similarly affected, perineal samples from patients within this cohort who had been admitted directly to the ICU (n = 206) were cultured at admission (< 48-h ICU stay) and again after 3 days of cycle-specified antibiotic (FEP or APP-β) [5]. Resistance to gentamicin and APP-β were chosen as key phenotypes not associated with cefepime resistance. Resistant Enterobacteriaceae were cultured from a modest proportion at admission (to gentamicin, 14%; to APP-β, 26%) but with no cumulative increase over time, as for MRSA and Pseudomonas [5]. Colonization by APP-β-resistant Enterobacteriaceae increased significantly overall after ICU admission (p = 0.015) but was almost 2.5 times more likely after cefepime than APP-β exposure (p < 0.05) (Fig. 1).

Fig. 1.

Variation in colonization patterns before and after ICU stay. a Rates of colonization with antibiotic-resistant species at admission and after ICU stay. b Change in susceptibility rates after ICU stay in different treatment cycles. Proportion of the entire study group of patients (n = 206) with positive cultures. “Any resistance” indicates any bacterial growth on antibiotic supplemented media. “All resistance” indicates any growth on ChromAgar™ supplemented with vancomycin only (to exclude Gram-positive species). *KESC, Klebsiella, Enterobacter, Serratia, Citrobacter spp. as identified on colorimetric media ChromAgar™ and confirmed by MALDI-TOF [16] as previously described [5]. Asterisks (*, **, ***) above bar charts indicate significant differences (p < 0.05)

Patients without resistant Enterobacteriaceae on admission were more likely to remain free of them after treatment with APP-β (or no drug) than cefepime (Fig. 1; *p = 0.004), and this association held when APP-β and cefepime treatment were directly compared (n = 45 vs. 22, p = 0.016). This was also true for APP-β (Fig. 1; **p = 0.002) and gentamicin resistance (Fig. 1; ***p = 0.014) when considered individually (Table 1). Backwards stepwise logistic regression analysis also linked cefepime exposure more strongly to later APP-β-resistance (OR 2.285 (CI 1.096–4.764); p = 0.027) than length of stay, age, or admission APACHE II score. Cefepime was also more strongly associated with APP-β-resistant Escherichia coli than APP-β itself (Pearson’s chi-square test, p = 0.027).

Table 1.

Effect of antibiotic on gain and loss of resistance in Enterobacteriaceae after 72 h in ICU

Resistance	Treatmenta	Gainedb	Lostb	No changec
				Sensitive	Resistant
Timentin and/or gentamicin	Cefepime	15	7	22	17
	APP-β	14	6	45c	13
	None	13	3	43a	8
		p = 0.610	p = 0.34	p = 0.004a	p = 0.07
Timentin	Cefepime	15	8	22	16
	APP-β	14	6	45a	13
	None	12	3	44a	8
		p = 0.550	p = 0.20	p = 0.002a	p = 0.10
Gentamicin	Cefepime	8	7	39	7
	APP-β	6	8	62a	2
	None	5	2	57a	3
		p = 0.456	p = 0.16	p = 0.014a	p = 0.06

^aAPP-β, antipseudomonal penicillin/β-lactamase; none, no cefepime or APP-β

^bNumber of patients

^cSignificant difference (p < 0.05)

Our analysis showed that high-level homogeneity of β-lactam antibiotics within cycles was not associated with overall increased resistance, in agreement with other studies on antibiotic cycling in which Gram-negative bacterial susceptibility was not significantly altered [2, 6, 7]. The apparent ecological effects that we describe are consistent with our own data regarding MRSA and P. aeruginosa [5], challenging antimicrobial homogeneity as a driver of resistance per se [8], an idea that was premised on a mathematical model which was recently disputed [9]. Antibiotic use is recognized as the single most powerful selective pressure for the emergence of resistance particularly in environments where usage is high (ICU). However, the different strategies implemented to curb the rise of resistance in hospitals, including cycling, have had variable outcomes due to the complex relationship between use of specific drugs and resistance patterns in bacterial populations [10]. In our study, despite stable overall resistance rates, treatment with cefepime was a significant independent predictor of acquisition of antibiotic-resistant Gram-negative organisms and was also strongly associated with increased resistance to APP-β, but not to cefepime or extended-spectrum β-lactams (Table 1), in agreement with other studies on cefepime use in hospitalized patients [6, 11].

Our data strongly point to in vivo ecological effects of antibiotics rather than specific selection pressure associated with use of a specific antimicrobial class. However, ecological perturbation does not readily explain gentamicin and β-lactam resistance after cefepime, as these phenotypes are typically plasmid-encoded in the Enterobacteriaceae. We therefore directly compared E. coli populations from each of 12 patients before and after cefepime treatment (Additional file 1: Methods) and found no increase in virulence-associated types nor dominance of any single resistant clone (Table 2). Cultured isolates were of limited diversity, almost all of the B2 and D phylogenetic subtypes. There were three or less clearly distinguishable restriction types, and antibiotic resistance phenotypes gave no hint of underlying processes. However, a general effect on mobile genetic elements was suggested by the increased complexity and abundance of self-transmissible resistance plasmids and by enrichment for mobile resistance genes not relevant to cefepime (e.g., strAB, bla_TEM, bla_SHV; Fig. 2).

Table 2.

Antimicrobial resistance (AR) profiles of isolated E. coli representatives

Patient	Isolate†	AR phenotype‡	AR genotype§
1B	a B2 a D/E	None None	None
1A	c B2	None	None
2B	d B2 e B2	None None	None
2A	e B2 d B2	None None	None
3B	f B2 f1 B2 h D/E	None TET TET	tet(B) aphA1 dfrA14 strA strB sul2
3A	f1 B2-D/E h D/E	TET TET	tet(B)
4B	i B2	AMP AMC CFZi TIMi	bla TEM sul2
4A	k B2 m D/E	AMP CFZi CHLi AMP	aadA blaSHV In
5B	n B2	AMP CFZi TIMi	aadA blaTEM In
5A	n B2	AMP CFZi TIMi	aadA blaTEM In
6B	p B2-unk	AMP AMC TZP TIM CHL	aadA blaOXA-1 catA1 In
6A	q B2 r B2	None AMP CFZi TIMi TET	blaTEM tet(A)
7B	s F	AMP CFZi TMP SXT	bla TEM dfrA14 sul2 strA strB
7A	s1 D/E s2 F s2 D/E	AMP AMCi CFZ TZP TIM TMP SXT AMP AMCi CFZ TZP TIM TOBi TMP SXT AMP AMCi CFZ TIM TMP SXT	bla TEM dfrA14 strA strB sul2
8B	t B2	AMP CFZi TIMi	aadA blaTEM In
8A	t B2	AMP AMCi CFZ TIM	aadA blaTEM In
9B	u B2 v B2	AMP AMCi CFZi None	bla TEM
9A	u B2	AMP AMCi CFZi TIMi	bla TEM
10B	z B1 z1 B1 z2 B1	TET TET TET	tet(B)
10A	w B2 y unk	None AMP TIMi TMP SXT	bla TEM dfrA5 strA strB sul2
11B	w B2	None	none
11A	aa D/E	AMP AMC AZ CFZ FOX CAZ CRO LEX TIMi	blaCMY-2-like
12B	bb B1 cc B1	AMP CFZi TIMi TMP SXT AMP TIMi CHLi TMP SXT	blaTEM catA1 dfrA7 In
12A	dd B2 ee B2	AMP AMCi CFZi TIM AMP AMCi CFZ TIMi	bla TEM

Underlined data not detected phenotypically by the BD Phoenix^TMP system

B before antibiotic treatment (< 48 h ICU stay), A after antibiotic treatment (≥ 72 h ICU stay), i intermediate, In class 1 integron 5′- and/or 3′-conserved segments

^†Defined by PFGE pattern (“a” to “ee”) and by phylogenetic grouping (A, B1, B2, D/E, F, unk (unknown) [19])

^‡Not susceptible by BD Phoenix^TMP screening of single E. coli colonies

^§Genotype determined by NGS sequencing data analysis of pooled E. coli representatives for each patient, using BLAST comparisons [20] to the MARA database [17] and our in-house database of rep and mobilization genes (Additional file 1: Table S1)

Fig. 2.

Antibiotic resistance markers detected before and after cefepime exposure in E. coli isolates from ICU patients. Resistance genes (a), plasmid replication genes (b), and plasmid transfer markers (c) were identified using the sequencing output from MiSeq sequencing (250 bp; paired-end) of pooled representatives (2–6 colonies per patient) of the E. coli population before (black) and after (white) cefepime treatment. Markers were detected by alignment with resistance genes and mobile genetic elements in the MARA database [17] and plasmids markers in our in-house database (Additional file 1 Methods). aad includes aadA1, aadA6, and aadA10; “transfer” comprises marker genes for conjugation/self-transmission (tra, nik, etc.); “mobilization” indicates relaxase genes of mobilizable plasmid types (Additional file 1: Table S1) [18]

In animal models, a proteobacterial bloom that accompanies colitis was associated with accelerated plasmid transfer between species [12], and a similar proteobacterial bloom is relatively prolonged after third-generation cephalosporins compared to penicillins [13, 14], providing a potential biological explanation for our findings (Fig. 2). Antibiotic treatment modifies the microbial community structure in the gut by shifting the competitive balance between sensitive bacteria and resistant/pathogenic subpopulations [15]. These subpopulations carry different resistant determinants that may come to predominate both by amplification of the original carriers and/or spread to other species. In Gram-negative enterobacteria, antibiotic resistance develops mainly via horizontal transfer of resistance genes that often cluster together in the same genetic locus, either on the chromosome or on plasmids, giving rise to multiple resistant types. Use of one antibiotic may drive selection of resistance to an entirely different class of drugs due to both cross-resistance mechanisms and co-localization of genetic elements. Perhaps more importantly resistance determinants are also associated with diverse mobile genetic elements (transposons, insertion sequences, plasmids) that allow for the movement of multidrug resistance loci between bacterial cells [15].

Even though selection and spread of specific resistance might be constrained by fitness requirements, antibiotic activity itself is known to promote horizontal gene transfer by triggering recombination and conjugation events, which will affect population-level resistance patterns [15], and by acceleration of gene transfer during population expansion events [13]. Together, these data indicate that cefepime exposure differentially drives antibiotic resistance in the microflora other than by direct phenotypic selection and are consistent with descriptions of enhanced plasmid transfer in other gut dysbioses [13]. This provides a potential explanation for resistance (e.g., to extended-spectrum β-lactam antibiotics) in Enterobacteriaceae that has been linked to exposure to late-generation cephalosporins, such as cefepime [14], and seems likely generalizable to third-generation cephalosporins, which have similar activities, gut penetration and associations with antibiotic resistance. It appears unlikely from (narrower-spectrum) first-generation cephalosporins, but reminds us that unmeasured impacts on the microbiome are key outcome determinants that have yet to be fully explored.

Authors’ contributions

CV designed and performed all analyses for the E. coli characterization study, participated in the analysis of clinical data, and wrote the manuscript. ANG performed the initial culture work for resistance data from the clinical specimens and analysis of clinical data and participated in clinical study design and manuscript preparation. BEW performed the analysis of clinical data. GT supported the bioinformatic screening of sequencing data for resistance, mobile element, and plasmid markers. IP participated in the study design. SRP participated in the study design and analysis of sequence data and created the plasmid marker database. JRI designed the study, supervised all analysis, and wrote the manuscript. All authors approved the final version of the manuscript.

Ethics approval and consent to participate

The previously published clinical component in the parent study (Ginn et al. 2012 [5]) was conducted under a waiver of consent, under the auspices of the relevant Human Research Ethics Committees of the Sydney West Area Health Service and the Royal Brisbane and Women’s Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.